Epitranscriptome refers to all changes related to transcriptome function that is not related to changes in ribonucleotide sequence. This is a new layer of regulation of RNA expression, including processing, splicing, stability, localization and translation, mainly mediated by RNA modifications such as the m6A and m5C, RNA editing, noncoding RNA (ncRNA) or RNA binding proteins (RBPs), etc., and has been increasingly recognized for their important roles in physiologic and pathologic processes. Accumulating evidence suggests that alterations in RNA regulation by ncRNAs, RBPs, RNA modification or editing play critical roles in cancer initiation, progression and therapeutic response. In addition, potential targeted RNA levels, such as ncRNAs or RNA modification modulators, are highlighted as diagnostic, prognostic, or therapeutic targets for cancer, including shaping tumor immunity and response to immunotherapy.
This Research Topic aims to dissect the functional RNAs, which have been linked to hallmarks of cancer. The epitranscriptome is an open concept in which the fate of transcripts is determined by various mechanisms at the RNA level. We will focus on recent advances in epitranscriptome: the identification and underlying mechanism of regulatory ncRNAs; mapping RNA modifications and editing, and identifying potential new regulators including writers, erasers and readers; determination of regulatory motifs and function by RBPs; especially their important function and signaling pathways in cancer. These studies will provide important insights into the underlying mechanisms of cancer initiation, progression and therapeutic response. More importantly, it is worthy to explore whether RNA and related modulator proteins can be utilized as biomarkers for early detection of cancer and prediction of therapeutic response, or as novel therapeutic targets for cancer treatment to optimize the clinical benefit.
In this Research Topic, we welcome submissions of original research works and reviews, which include but are not limited to, the following themes:
• The role of lncRNAs and other ncRNAs in cancer initiation, progression and antitumor immune response.
• The abnormality of RNA modifications and its regulators, such as writers, erasers and readers, in various types of cancer.
• The mechanisms and potential targets that improve the efficacy of anti-tumor therapeutics, including immunotherapies.
• Identification of biomarkers for early detection of cancer and prediction of therapeutic response.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Epitranscriptome refers to all changes related to transcriptome function that is not related to changes in ribonucleotide sequence. This is a new layer of regulation of RNA expression, including processing, splicing, stability, localization and translation, mainly mediated by RNA modifications such as the m6A and m5C, RNA editing, noncoding RNA (ncRNA) or RNA binding proteins (RBPs), etc., and has been increasingly recognized for their important roles in physiologic and pathologic processes. Accumulating evidence suggests that alterations in RNA regulation by ncRNAs, RBPs, RNA modification or editing play critical roles in cancer initiation, progression and therapeutic response. In addition, potential targeted RNA levels, such as ncRNAs or RNA modification modulators, are highlighted as diagnostic, prognostic, or therapeutic targets for cancer, including shaping tumor immunity and response to immunotherapy.
This Research Topic aims to dissect the functional RNAs, which have been linked to hallmarks of cancer. The epitranscriptome is an open concept in which the fate of transcripts is determined by various mechanisms at the RNA level. We will focus on recent advances in epitranscriptome: the identification and underlying mechanism of regulatory ncRNAs; mapping RNA modifications and editing, and identifying potential new regulators including writers, erasers and readers; determination of regulatory motifs and function by RBPs; especially their important function and signaling pathways in cancer. These studies will provide important insights into the underlying mechanisms of cancer initiation, progression and therapeutic response. More importantly, it is worthy to explore whether RNA and related modulator proteins can be utilized as biomarkers for early detection of cancer and prediction of therapeutic response, or as novel therapeutic targets for cancer treatment to optimize the clinical benefit.
In this Research Topic, we welcome submissions of original research works and reviews, which include but are not limited to, the following themes:
• The role of lncRNAs and other ncRNAs in cancer initiation, progression and antitumor immune response.
• The abnormality of RNA modifications and its regulators, such as writers, erasers and readers, in various types of cancer.
• The mechanisms and potential targets that improve the efficacy of anti-tumor therapeutics, including immunotherapies.
• Identification of biomarkers for early detection of cancer and prediction of therapeutic response.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
